Literature DB >> 17586742

Preemptive isolation to prevent methicillin-resistant Staphylococcus aureus cross-transmission in diabetic foot.

Emmanuelle Lecornet1, Jérôme Robert, Sophie Jacqueminet, Ha Van Georges, Sandrine Jeanne, Florence Bouilloud, Christine Veyrie, Vincent Jarlier, André Grimaldi, Agnès Hartemann-Heurtier.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17586742     DOI： 10.2337/dc07-0743

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  5 in total

Review 1.  Methicillin-resistant Staphylococcus aureus in diabetic foot infections.

Authors:  Ioanna Eleftheriadou; Nicholas Tentolouris; Vasiliki Argiana; Edward Jude; Andrew J Boulton
Journal:  Drugs       Date:  2010-10-01       Impact factor: 9.546

2.  A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections.

Authors:  Inge C Gyssens; Matthew Dryden; Peter Kujath; Dilip Nathwani; Nicolaas Schaper; Barbara Hampel; Peter Reimnitz; Jeff Alder; Pierre Arvis
Journal:  J Antimicrob Chemother       Date:  2011-09-06       Impact factor: 5.790

3.  Pre-emptive contact precautions for intubated patients reduced healthcare-associated meticillin-resistant Staphylococcus aureus transmission and infection in an intensive care unit.

Authors:  A Matsushima; O Tasaki; K Tomono; H Ogura; Y Kuwagata; H Sugimoto; T Hamasaki
Journal:  J Hosp Infect       Date:  2011-04-06       Impact factor: 3.926

4.  Larval therapy for leg ulcers (VenUS II): randomised controlled trial.

Authors:  Jo C Dumville; Gill Worthy; J Martin Bland; Nicky Cullum; Christopher Dowson; Cynthia Iglesias; Joanne L Mitchell; E Andrea Nelson; Marta O Soares; David J Torgerson
Journal:  BMJ       Date:  2009-03-19

5.  Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.

Authors:  N C Schaper; M Dryden; P Kujath; D Nathwani; P Arvis; P Reimnitz; J Alder; I C Gyssens
Journal:  Infection       Date:  2012-11-23       Impact factor: 3.553
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.